Company & Idea: Jena Bioscience was founded in 1998 by a team of scientists from the Max Planck Institute of Molecular Physiology (Dortmund). With more than 25 years of know-how, it develops and researches innovative reagents for research and industry clients in over 100 countries. Jena Bioscience is constantly developing new products and technologies. It produces nucleotides & nucleotide analogues, reagents for protein crystallisation, the protein expression system "LEXSY", enzymes, recombinant proteins, PCR products, antibodies, affinity chromatography products, fluorescent probes. Protein expression systems are a research priority. In the field of protein crystallisation, it is one of the world's leading companies. Protein crystallisation is used in particular for basic research and the development of drugs.

Jena Bioscience is a Jena-based owner-managed company with about 50 employees. For some of its projects, Jena Bioscience receives funding from the Free State of Thuringia, the European Regional Development Fund (ERDF / ERDF) and the European Social Fund (ESF).

Project: RNAEpiTrans. The project aims to establish a production system for the single-stage production of customised biologically functional synthetic RNA. The production system will improve the yield and range of enzymatically insertable epigenetic modifications compared to standard T7-RNA polymerase-based methods.

The following speaks for Jena Bioscience: Biotechnology is a booming growth industry, but for many people, the field is difficult to understand. The company is highly specialised in this field. It develops products for an international market, e.g. medicine, pharmaceuticals, energy supply, chemical industry. Its customers are located all over the world. It develops products that can replace previous environmentally harmful applications with more advantageous biotechnical processes. The company conducts basic research. It is an excellent example of successful entrepreneurship from science as well as research in companies. The project covers the thematic fields of research, development and innovation and from Priority 2, "Competitiveness of Companies".